TY - JOUR
T1 - Clinical relevance of circulating cell-free microRNAs in cancer
AU - Schwarzenbach, Heidi
AU - Nishida, Naohiro
AU - Calin, George A.
AU - Pantel, Klaus
N1 - Funding Information:
G.A.C. is The Alan M. Gewirtz Leukemia & Lymphoma Society Scholar. He was also supported as a Fellow at The University of Texas MD Anderson Research Trust, as a University of Texas System Regents Research Scholar. Work in G.A.C.’s laboratory is supported in part by the US National Institutes of Health (NIH)/US National Cancer Institute (NCI) grants 1UH2TR00943-01 and 1R01 CA182905-01; a US Department of Defence Breast Cancer Idea Award; Developmental Research Awards in breast cancer, ovarian cancer, brain cancer, prostate cancer, multiple myeloma and leukaemia (P50 CA100632) as well as head and neck cancer (P50 CA097007) from the Specialized Programs of Research Excellence (SPOREs); by the CLL Global Research Foundation; a Sister Institution Network Fund (SINF) grant from the MD Anderson Cancer Centre and the German Cancer Research Centre (DKFZ) in chronic lymphocytic leukaemia; a SINF grant in colorectal cancer, the Laura and John Arnold Foundation; the RGK Foundation; and The Estate of C. G. Johnson Jr. K.P. is recipient of the European Research Council Advanced Investigator grant “DISSECT” (no. 269,081), and his work is supported by grants of the Deutsche Forschungsgemeinschaft (DFG), Federal Minister of Education and Science (BMBF) and Deutsche Krebshilfe. The authors apologize to all colleagues whose work was not cited because of space restrictions.
PY - 2014/3
Y1 - 2014/3
N2 - Efficient patient management relies on early diagnosis of disease and monitoring of treatment. In this regard, much effort has been made to find informative, blood-based biomarkers for patients with cancer. Owing to their attributes - which are specifically modulated by the tumour - circulating cell-free microRNAs found in the peripheral blood of patients with cancer may provide insights into the biology of the tumour and the effects of therapeutic interventions. Moreover, the role of microRNAs in the regulation of different cellular processes points to their clinical utility as blood-based biomarkers and future therapeutic targets. MicroRNAs are optimal biomarkers owing to high stability under storage and handling conditions and their presence in blood, urine and other body fluids. In particular, detection of levels of microRNAs in blood plasma and serum has the potential for an earlier cancer diagnosis and to predict prognosis and response to therapy. This Review article considers the latest developments in the use of circulating microRNAs as prognostic and predictive biomarkers and discusses their utility in personalized medicine.
AB - Efficient patient management relies on early diagnosis of disease and monitoring of treatment. In this regard, much effort has been made to find informative, blood-based biomarkers for patients with cancer. Owing to their attributes - which are specifically modulated by the tumour - circulating cell-free microRNAs found in the peripheral blood of patients with cancer may provide insights into the biology of the tumour and the effects of therapeutic interventions. Moreover, the role of microRNAs in the regulation of different cellular processes points to their clinical utility as blood-based biomarkers and future therapeutic targets. MicroRNAs are optimal biomarkers owing to high stability under storage and handling conditions and their presence in blood, urine and other body fluids. In particular, detection of levels of microRNAs in blood plasma and serum has the potential for an earlier cancer diagnosis and to predict prognosis and response to therapy. This Review article considers the latest developments in the use of circulating microRNAs as prognostic and predictive biomarkers and discusses their utility in personalized medicine.
UR - http://www.scopus.com/inward/record.url?scp=84896703318&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896703318&partnerID=8YFLogxK
U2 - 10.1038/nrclinonc.2014.5
DO - 10.1038/nrclinonc.2014.5
M3 - Review article
C2 - 24492836
AN - SCOPUS:84896703318
SN - 1759-4774
VL - 11
SP - 145
EP - 156
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 3
ER -